Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Regeneron Pharmaceuticals, Inc. capped off 2021 squeezing one last bit of juice from its COVID-19 antibody cocktail, which along with Eylea (aflibercept) and Sanofi-partnered Dupixent (dupilumab) helped generate much of the company’s sales growth – but the company anticipates no revenue in the near term from the Roche Holding AG-partnered cocktail, REGEN-COV/Ronapreve (casirivimab/imdevimab) due to lack of efficacy against Omicron. Instead, management is playing up the potential for long-term sales growth in its pipeline.

On 4 February, the company reported fourth quarter 2021 revenues of $5bn and full year revenues of $16.1bn, respectively increases...